Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Comment: Blinatumomab for acute lymphocytic leukaemia

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.14
Views: 2523

Dr Catherine Bollard - George Washington University, Washington, USA

Dr Bollard talks to ecancertv about key abstracts showcased at ASH 2014. Here, she addresses Dr Nicola Gökbuget's study on the use of blinatumomab for the treatment of acute lymphocytic leukaemia. 

Read the news story here. 

Dr Bollard is also a member of the Division of the Blood and Marrow Transplantation and senior scientist at the Children National Health System's Center for Cancer and Immunology Research at Children’s Research Institute. She is the Principal Investigator and the Sheikh Zayed Institute for Pediatric Surgical Innovation.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation